Expres2ion Biotech

 

CLICK HERE FOR INFORMATION ABOUT THE 2022 RIGHTS ISSUE

Financial Calendar

• 18/08/22

  Half-year report, 2022

• 17/11/22

  Interim report, Q3 2022

• 09/02/23

  Year-end report, 2022

Latest press releases

Updated Phase III trial for the ABNCoV2 COVID-19 vaccine to include a licensed mRNA vaccine

16-06-2022 Regulatory pressrelease

Hørsholm, Denmark, June 16, 2022 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that Bavarian Nordic’s upcoming Phase III clinical trial to evaluate the ABNCoV2 capsid virus-like particle (cVLP) based COVID-19 vaccine has been redesigned due to a licensed mRNA vaccine now being available as a comparator vaccine. This enables the design…

Read more

Analysguiden publishes research report setting price target of SEK 30 with an optimistic fair value of SEK 60

13-06-2022 Non-regulatory pressrelease

Hørsholm, Denmark, June 13, 2022 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that Analysguiden has updated their research reports on ExpreS2ion in June, following the publication of Q1 2022 results, the positive Phase II COVID-19 results for the ABNCoV2 vaccine with respect to omicron protection, and progression of the preclinical-stage breast…

Read more

View all